Bulk Pharmaceutical API Sources for EPTIFIBATIDE

Bulk Pharmaceutical API Sources for EPTIFIBATIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-006-069-141
Amadis Chemical		A808724
Amadis Chemical		A813250
AKos Consulting & Solutions		AKOS015895205

Eptifibatide Bulk API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the current landscape of bulk active pharmaceutical ingredient (API) sourcing for eptifibatide, a non-peptide glycoprotein IIb/IIIa inhibitor used in the treatment of acute coronary syndromes. The analysis focuses on key manufacturers, their production capacities, regulatory compliance, and potential supply chain risks.

What are the primary global suppliers of eptifibatide API?

The global supply of eptifibatide API is concentrated among a limited number of manufacturers. These suppliers are critical for ensuring a consistent and compliant supply chain for finished drug product manufacturers. Key players include:

• Chirag Laboratories: Based in India, Chirag Laboratories is a significant producer of eptifibatide API. The company has established manufacturing facilities compliant with international standards. Their reported capacity and market presence indicate a substantial role in the global supply.
• Abbott Laboratories: As the originator of eptifibatide (under the brand name Integrilin), Abbott Laboratories has historically been a primary source. While they may focus on their branded product, their internal API production capabilities remain a factor in the market. Information on their current external API sales is proprietary.
• Various Contract Manufacturing Organizations (CMOs): Several CMOs, particularly in India and China, possess the technical expertise and infrastructure to produce eptifibatide API. These entities often supply generic drug manufacturers. Specific names are less consistently disclosed publicly but are vital components of the supply chain. For example, companies specializing in peptide synthesis are often involved.

What is the regulatory status and compliance of eptifibatide API manufacturers?

Regulatory compliance is paramount for API manufacturers, ensuring product quality, safety, and efficacy. Eptifibatide API manufacturers must adhere to Good Manufacturing Practices (GMP) as defined by major regulatory bodies.

• FDA Compliance: Manufacturers supplying to the U.S. market must have their facilities inspected and approved by the U.S. Food and Drug Administration (FDA). This includes submitting Drug Master Files (DMFs) detailing the API’s manufacturing process, quality controls, and specifications.
• EMA Compliance: Manufacturers targeting the European Union market require compliance with European Medicines Agency (EMA) regulations. This often involves Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) or equivalent documentation.
• Other Regulatory Bodies: Compliance with the regulations of other national health authorities, such as Health Canada, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and India’s Central Drugs Standard Control Organisation (CDSCO), is also crucial for market access.
• Audits and Inspections: API manufacturers undergo regular audits by their customers (finished drug product manufacturers) and by regulatory agencies. These audits verify adherence to GMP standards, including quality assurance, quality control, facility maintenance, and personnel training.
• Impurity Profiling and Control: Stringent control over impurities, including residual solvents, heavy metals, and process-related impurities, is a critical aspect of regulatory compliance. Manufacturers must demonstrate robust analytical methods for detecting and quantifying these substances.

What are the typical production capacities and lead times for bulk eptifibatide API?

Production capacity and lead times are key considerations for supply chain management and market responsiveness.

• Estimated Capacity: While precise figures are often proprietary, manufacturers of eptifibatide API are understood to have capacities ranging from tens to hundreds of kilograms per batch, depending on the scale of their operations and market demand. The total global capacity is sufficient to meet current market needs, but can be strained by sudden demand spikes or supply chain disruptions.
• Batch Sizes: Eptifibatide is a peptide, and its synthesis involves complex multi-step chemical processes. Batch sizes are determined by reactor volumes and the efficiency of the synthetic route. Typical batch sizes can range from 50 kg to 200 kg.
• Lead Times: Standard lead times for bulk API orders can range from 3 to 6 months. This period accounts for raw material procurement, multi-stage synthesis, purification, quality control testing, and documentation. Expedited production may be possible but typically incurs higher costs and requires strong supplier relationships.
• Factors Affecting Lead Times:
  • Raw Material Availability: Certain specialized reagents or starting materials for peptide synthesis can have their own production lead times, impacting the overall API synthesis schedule.
  • Production Scheduling: The manufacturer's existing production schedule and backlog significantly influence when an order can commence.
  • Quality Control Release: The time required for comprehensive QC testing and release of the API batch can add several weeks to the lead time.
  • Regulatory Documentation: Preparation and submission of necessary regulatory documentation can also influence the timeline.

What are the key quality control parameters for eptifibatide API?

Ensuring the quality of eptifibatide API is critical for patient safety and therapeutic efficacy. Key quality control parameters include:

• Assay (Purity): The API must meet a specified purity level, typically determined by High-Performance Liquid Chromatography (HPLC). Purity requirements are generally above 98%.
• Related Substances/Impurities: Specific limits are set for known and unknown related substances, including synthesis by-products, degradation products, and enantiomeric impurities. These are also quantified using HPLC.
• Residual Solvents: Limits for residual organic solvents used during synthesis and purification are defined by ICH Q3C guidelines. Gas Chromatography (GC) is typically used for analysis.
• Water Content: Determined by Karl Fischer titration, controlling water content is essential for API stability.
• Heavy Metals: Limits for heavy metals are specified to ensure the absence of toxic metallic impurities. Inductively Coupled Plasma Mass Spectrometry (ICP-MS) or Atomic Absorption Spectroscopy (AAS) are common methods.
• Chiral Purity: As eptifibatide is a chiral molecule, enantiomeric purity is a critical parameter, often assessed by chiral HPLC or other specialized chromatographic techniques.
• Bacterial Endotoxins: For injectable drug products, the API must meet strict limits for bacterial endotoxins, assessed using the Limulus Amebocyte Lysate (LAL) test.
• Appearance: The physical appearance of the API (e.g., color, physical state) is visually inspected.
• Identification: Spectroscopic methods (e.g., Infrared spectroscopy, Mass Spectrometry) and chromatographic retention times are used to confirm the identity of the API.

What are the risks associated with eptifibatide API sourcing?

Sourcing eptifibatide API involves several potential risks that drug manufacturers and investors must consider.

• Supply Chain Disruptions:
  • Geopolitical Instability: Reliance on suppliers in specific geographic regions can expose the supply chain to risks from political unrest, trade disputes, or natural disasters.
  • Raw Material Shortages: Interruption in the supply of key starting materials or reagents for peptide synthesis can halt API production.
  • Manufacturing Facility Issues: Unexpected plant closures due to accidents, environmental incidents, or regulatory sanctions can immediately impact supply.
• Regulatory Non-Compliance:
  • FDA/EMA Warning Letters or Bans: A regulatory agency's issuance of a warning letter or import alert against an API manufacturer can halt the supply of API to that market.
  • Changes in Regulatory Requirements: Evolving regulatory expectations for impurity control or analytical methods can necessitate costly process revalidation.
• Quality Issues:
  • Batch Failures: A single API batch failing to meet stringent quality specifications can lead to significant delays and write-offs.
  • Counterfeit API: While less common for established products, the risk of counterfeit API entering the supply chain, especially from less regulated sources, remains.
• Intellectual Property (IP) and Patent Landscape:
  • Ongoing Litigation: While the primary patents for eptifibatide have expired, potential litigation related to manufacturing processes or specific formulations can create uncertainty.
  • New Entrant IP: Emerging manufacturers might develop proprietary synthesis routes or purification methods, leading to new IP considerations.
• Price Volatility:
  • Raw Material Cost Fluctuations: The cost of amino acids, coupling reagents, and solvents can fluctuate, impacting API manufacturing costs and, consequently, API pricing.
  • Market Competition: Increased competition from new generic API manufacturers can drive down prices, but may also incentivize cost-cutting that could affect quality.
• Limited Number of Suppliers: The relatively small number of established, high-quality eptifibatide API manufacturers creates a concentrated supply risk. If one major supplier experiences issues, the impact on the global market can be substantial.

What is the patent expiry and generic market outlook for eptifibatide?

The patent landscape significantly influences the availability of generic eptifibatide API and finished drug products.

• Compound Patent Expiry: The primary patents covering the eptifibatide molecule itself have expired in major markets, including the United States and Europe. For example, U.S. Patent No. 5,192,747, related to cyclic RGD peptides, expired in 2007.
• Formulation and Method of Use Patents: While compound patents have expired, other patents covering specific formulations, dosages, or methods of use may still be in effect or have expired more recently. These can influence the speed and nature of generic market entry.
• Generic Entry: With the expiry of key patents, generic manufacturers have entered or are capable of entering the market for eptifibatide drug products. This typically leads to increased competition and downward pressure on pricing for both finished products and API.
• ANDA Filings: Companies seeking to market generic eptifibatide in the U.S. must file Abbreviated New Drug Applications (ANDAs) with the FDA, demonstrating bioequivalence to the reference listed drug (Integrilin®). The approval of these ANDAs signals the official entry of generic competition.
• Market Dynamics: The generic market for eptifibatide API is driven by demand from generic finished product manufacturers. The availability of high-quality, cost-effective API from multiple reliable sources is crucial for the success of these generic products. The market share for generic eptifibatide is expected to grow as more generics achieve approval and market penetration.

What are the future trends in eptifibatide API sourcing?

Several trends are likely to shape the future of eptifibatide API sourcing.

• Diversification of Supply Chains: To mitigate risks associated with single-source dependency and geopolitical factors, companies are increasingly seeking to diversify their API suppliers across different geographical regions. This includes exploring secondary suppliers and building strategic partnerships.
• Increased Focus on Supply Chain Resilience: The COVID-19 pandemic highlighted vulnerabilities in global pharmaceutical supply chains. Future sourcing strategies will prioritize resilience, including robust inventory management, alternative logistics routes, and contingency planning.
• Technological Advancements in Peptide Synthesis: Innovations in solid-phase peptide synthesis, flow chemistry, and greener chemistry practices could lead to more efficient, cost-effective, and environmentally friendly production of eptifibatide API. This may enable new or smaller players to enter the market.
• Enhanced Regulatory Scrutiny: Regulatory agencies are continuously enhancing their oversight of API manufacturing. This will likely lead to stricter requirements for impurity profiling, process validation, and supply chain traceability, favoring manufacturers with mature quality systems.
• Consolidation in the CMO Landscape: The contract manufacturing sector for complex APIs like peptides may see consolidation, with larger, well-established CMOs acquiring smaller players to expand their capabilities and market reach. This could lead to fewer, but more capable, API suppliers.
• Regional Manufacturing Initiatives: Some countries are promoting domestic API manufacturing to reduce reliance on foreign sources. This could lead to the development of new manufacturing hubs for eptifibatide API in regions currently less prominent.

Key Takeaways

The eptifibatide API market is characterized by a concentrated supplier base, stringent regulatory requirements, and a growing generic landscape following patent expiries. Key suppliers, primarily in India and historically from the originator, are essential for meeting global demand. Robust quality control measures and adherence to GMP are non-negotiable. Sourcing strategies must account for risks including supply chain disruptions, regulatory non-compliance, and price volatility. Future trends point towards enhanced supply chain resilience, technological advancements in synthesis, and increased regulatory oversight.

FAQs

1. Are there any active patents that would prevent the manufacturing of eptifibatide API? The primary compound patents for eptifibatide have expired. However, patents related to specific manufacturing processes or formulations might still be relevant and require careful review by prospective API manufacturers.
2. What is the typical shelf life of bulk eptifibatide API? The shelf life of bulk eptifibatide API, when stored under recommended conditions (typically cold and protected from light and moisture), is generally between 24 to 36 months. Specific stability data is provided by the API manufacturer.
3. Can eptifibatide API be sourced from multiple regions to mitigate supply chain risk? Yes, while major suppliers are concentrated, it is possible to identify and qualify API manufacturers in different regions, such as India and potentially others, to build a diversified supply chain.
4. How does the synthesis of eptifibatide API differ from small molecule APIs? Eptifibatide is a peptide, synthesized through complex multi-step chemical reactions involving sequential coupling of amino acids. This differs from small molecule APIs, which are typically produced through fewer, more direct chemical transformations. Peptide synthesis requires specialized expertise and equipment.
5. What are the implications of the 2023 ICH Q3D guideline on elemental impurities for eptifibatide API manufacturers? ICH Q3D requires manufacturers to perform a risk assessment to identify and control elemental impurities. Eptifibatide API manufacturers must evaluate potential sources of elemental impurities throughout their manufacturing process and implement controls to ensure compliance with specified limits for elements such as lead, arsenic, cadmium, and mercury.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA website] (Note: Specific URL for DMF information is dynamic and best accessed via FDA's site search for "Drug Master Files"). [2] European Medicines Agency. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from [EMA website] (Note: Specific URL for CEP information is dynamic and best accessed via EMA's site search for "CEP"). [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2013). ICH Harmonised Guideline Q3C(R6): Impurities: Guideline for Residual Solvents. [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Guideline Q3D: Guideline for Elemental Impurities. [5] U.S. Food and Drug Administration. (n.d.). Abbreviated New Drug Application (ANDA) Pathway. Retrieved from [FDA website] (Note: Specific URL for ANDA information is dynamic and best accessed via FDA's site search for "ANDA").